tions are not increased and for whom the decision to treat with statin therapy is not otherwise clear.
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Numerous avenues of research ranging from basic experimental evidence to population-based observational studies have led to the recognition that cardiovascular disease (CVD) 3 has many features of a systemic inflammatory process (1 ) . Inflammation is a key element of the atherosclerotic process and contributes to all of its stages, from plaque initiation to subsequent growth and eventual rupture (2) (3) (4) .
High-sensitivity C-reactive protein (hsCRP) is an easily measured and widely investigated biomarker of inflammation. It is unclear whether CRP itself directly contributes to the pathophysiology of CVD. Supporting data for a role for CRP in atherothrombosis is limited to in vitro studies and experiments with animal models (5, 6 ) . Pepys et al. found that specific inhibition of CRP is feasible with a small-molecule synthetic compound [1,6-bis(phosphocholine)-hexane], which produces smaller infarct sizes in rats (7 ) .
Regardless of whether hsCRP plays a causal role in atherothrombosis, this biomarker has been proposed to be useful for improving CVD-risk prediction. A biomarker is thought to have clinical utility if it (a) adds to clinical knowledge; (b) provides risk information that is independent of established predictors; (c) is easy to obtain and interpret in a primary-care setting; (d) is accurate, reproducible, and internationally standardized; and (e) has a favorable cost-benefit ratio (8 ) . Screening biomarkers should also contribute to patient management, particularly through more accurate risk classification and guidance in the choice of therapy (8 ) .
Evidence from Observational Studies for hsCRP in Cardiovascular-Risk Assessment CARDIOVASCULAR DISEASE
More than 20 prospective studies of distinct cohorts have demonstrated that increased hsCRP concentrations are associated with an increased risk of incident CVD events after multivariate adjustment for traditional risk factors (Table 1 ) (9 ) . A smaller number of studies reported hsCRP to be positively associated with coronary events, but this association did not reach statistical significance after the results were adjusted for at least 4 other risk factors (Table 1) . A metaanalysis of 22 of these prospective studies found that individuals with hsCRP concentrations in the top tertile have an odds ratio of 1.45 (95% CI, 1.25-1.68) for major cardiac events after adjustment for traditional risk factors, compared with individuals in the lowest tertile (10 ) . In the studies that analyzed traditional risk factors in a way similar to hsCRP (i.e., multivariate analysis to assess the strength of independent association with CVD risk), the magnitude of the association of hsCRP concentration with incident CVD was comparable to that of LDL cholesterol (LDL-C) concentration, systolic blood pressure, or cigarette smoking.
Recent data from the Women's Health Study suggest that the addition of hsCRP concentration and family history of premature myocardial infarction to the ATP III (Adult Treatment Panel III) (Framingham) global risk score provides a more accurate assessment of CVD risk (11, 12 ) . Similarly, in asymptomatic men, the addition of hsCRP and family history improved risk classification (13 ) . The net reclassification index (NRI), a summary quantitative measure of model fit that compares the proportion of individuals moving up or down in risk categories with the use of a biomarker, has been used to assess whether hsCRP adds information to traditional risk factors. In the Women's Health Study, the NRI with hsCRP was 6% (14 ) , whereas the NRI with hsCRP in the Framingham Study was 5.6% for total CVD and 11.8% for hard coronary events (15 ) .
Thus, there are several prospective cohorts for which the addition of hsCRP measurement to CVDrisk scores reclassifies significant numbers (approximately 20%-30%) of intermediate-risk asymptomatic individuals (those with a 5%-20% CVD risk over a 10-year period) to a different risk category. This reclassification may have important implications for preventive pharmacotherapy for these individuals.
STROKE
Increased hsCRP concentrations correlate with an increased risk of developing stroke independent of traditional risk factors. Numerous prospective studies have demonstrated that higher hsCRP concentrations are associated with an increased risk of stroke, even after adjusting for multiple traditional risk factors, including blood pressure (9 ) . A smaller number of studies did not demonstrate a statistically significant association (9 ) . The data taken together indicate that the relative risk associated with increased hsCRP concentrations is comparable to that seen with other established risk factors for stroke, such as blood pressure.
METABOLIC SYNDROME AND DIABETES MELLITUS
hsCRP concentration has also been found to modify the risk associated with the metabolic syndrome. The syndrome encompasses a number of proatherogenic, prothrombotic, and proinflammatory risk factors: abdominal obesity, increased triglycerides, low HDL-C concentrations, high blood pressure, and high fasting glucose concentrations. This risk modification is thought to be due to the active role that adipocytes, particularly those in central or abdominal tissue, play in inflammatory vascular processes.
Increased hsCRP concentrations correlate with an increased risk of developing non-insulin-dependent diabetes mellitus. In addition, hsCRP concentration is associated with cardiovascular risk among individuals with the metabolic syndrome and appears to differentiate high-risk groups from low-risk groups for both incident diabetes mellitus and CVD events.
Multiple prospective cohort studies have confirmed hsCRP concentration to be associated with incident non-insulin-dependent diabetes mellitus independently of other risk factors such as obesity, especially in women (see Table 1 in the Data Supplement that accompanies the online version of this MiniReview at http://www.clinchem.org/content/vol55/ issue2) (9 ) . Among individuals who already have diagnosed diabetes mellitus, hsCRP concentrations further stratify cardiovascular risk, underscoring the pathophysiological link between insulin resistance, inflammation, and CVD (9 ) .
Clinical Trial Evidence for hsCRP in the Primary Prevention of CVD (JUPITER)
JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin) is a large multicenter international randomized clinical trial that was designed to directly assess whether statin therapy should be given to apparently healthy individuals with low LDL-C concentrations but increased hsCRP concentrations, a population that currently is not recommended for statin therapy (16 ) . 
STATIN THERAPY AND hsCRP
Hydroxymethylglutaryl-CoAreductaseinhibitors(statins) are the most widely studied lipid-lowering agents and the strongest LDL-C-lowering medications.
Statins lower LDL-C and total-cholesterol concentrations by approximately 20%-50% and have a smaller effect on lowering triglycerides (approximately 10%-40%) and raising HDL-C (approximately 5%-10%).
Most studies of the effect of statin agents on outcomes have shown that for approximately every 1% reduction in LDL-C concentration, there is an associated 1% reduction in relative risk in "hard" coronary events (myocardial infarction and coronary death) (17 ) . The Cholesterol and Recurrent Events (CARE) trial was the first to demonstrate that statin therapy also lowers plasma hsCRP concentrations (18 ) . These data are consistent with laboratory studies demonstrating that statins have antiinflammatory as well as lipid-lowering effects. This finding is now known to be a class effect of statins, which mediate reductions in hsCRP concentration of approximately 20%-30%. Although there is relatively little correlation between the degrees of LDL-C reduction and hsCRP reduction in individual patients (correlation coefficient, 0.1-0.2), the more potent statins generally produce more lowering of hsCRP as well as more lowering of LDL-C (19 -22 ) . In addition, a greater degree of CVD-event reduction with statin therapy occurs in hyperlipidemic patients with increased hsCRP concentrations than in patients with comparable cholesterol values and low hsCRP concentrations (21) (22) (23) (24) . A post hoc analysis from the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) showed that individuals with low LDL-C and high hsCRP concentrations benefited from statin therapy, whereas those with low LDL-C and low hsCRP concentrations did not (22 ) . This finding of a higher risk associated with high hsCRP and low LDL-C concentrations is one of the motivating factors behind the JUPITER trial, because this group of apparently healthy individuals is generally missed by the current guidelines.
JUPITER TRIAL SUMMARY
The hypothesis of the JUPITER trial was that an inflammation biomarker such as hsCRP could be clinically useful in selecting higher-risk patients who may benefit from statin therapy despite having typical LDL-C concentrations. The primary objective of the JUPITER trial was to determine whether statin therapy would reduce the rate of first major cardiovascular events (defined as the combined endpoint of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or arterial revascularization) among individuals with LDL-C concentrations Ͻ130 mg/dL (Ͻ3.36 mmol/L) but hsCRP concentrations Ն2 mg/L. Fig. 1 in the online Data Supplement schematically depicts the basic JUPITER trial design. A total of 17 802 asymptomatic individuals (men Ն50 years and women Ն60 years) who had no history of coronary artery disease, stroke, or diabetes and who had initial-screening LDL-C and hsCRP concentrations of Ͻ130 mg/dL (Ͻ3.36 mmol/L) and Ն2.0 mg/L, respectively, were randomized in a double-blind fashion to receive either 20 mg/day rosuvastatin or placebo (25 ) . The trial, a well-designed investigator-initiated trial funded by AstraZeneca, was expected to last approximately 4 years. Unexpectedly, the independent data-monitoring board terminated the trial early in March 2008 (after approximately 2 years of follow-up) because rosuvastatin was more beneficial than expected in reducing incident CVD events compared with placebo and it was felt to be unethical to withhold rosuvastatin from the group assigned to placebo. Table 2 summarizes the differences between the patient population enrolled in the JUPITER trial and patient populations enrolled in previous statin trials conducted for primary prevention of CVD (25 ) . In particular, the median concentration of LDL-C in JUPITER was 108 mg/dL (2.79 mmol/L), with a 25th-75th percentile of 94 -119 mg/dL (2.43-3.08 mmol/L), which was lower than in previous trials. With an entry hsCRP criterion of Ն2.0 mg/L, the median hsCRP concentration was 4.3 mg/L, with most participants having hsCRP concentrations of 3 mg/L or greater (25th-75th percentile, 2.8 -7.1 mg/L). Approximately 40% of the participants had the metabolic syndrome at baseline. The trial screened 90 000 individuals to enroll the 17 802 participants, a screening-failure rate of approximately 80%. Half of those deemed ineligible had LDL-C concentrations Ն130 mg/dL (Ն3.36 mmol/L), and another 40% had hsCRP concentrations of Ͻ2 mg/L (25 ) .
The primary endpoint of combined incident CVD was reduced by 44% (Fig. 1) , with an important reduction in all-cause mortality of approximately 20% (26 ) . The relative reduction in the risk of CVD events was similar for myocardial infarction (54%), revascularization (47%), and stroke (48%). There was also a significant reduction in ischemic stroke without a concomitant increase in hemorrhagic stroke.
In JUPITER, a significant and similar reduction in CVD was seen across various subgroups of participants, in particular women, older individuals, and those with or without the metabolic syndrome (26 ) .
CVD risk was reduced (in terms of relative-risk reduction) to a similar extent in individuals with low and intermediate risk according to contemporary global risk scores (ATP III). A noteworthy finding is that participants with a family history of premature coronary
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Mini-Review heart disease (in a first-degree relative, a male Ͻ55 years or a female Ͻ65 years of age) had a greater relative reduction in the risk of CVD (65%) with statin treatment. Given its large sample size and the inclusion of a large number of women (n ϭ 6801) and members of ethnic groups (blacks, n ϭ 2225; Hispanics, n ϭ 2258), the JUPITER trial provides data on both the safety and benefit of statin use in these individuals, who have not been well represented in prior primary-prevention statin trials. Importantly, the safety profile of 20 mg of rosuvastatin daily in JUPITER was similar to that of other statins currently used in practice.
An interesting finding is the slightly but significantly higher risk of physician-reported diabetes in the statin arm compared with placebo, although there was no significant difference in fasting glucose concentrations. Whether this finding is related to higher body weights in the statin arm or to other mediating factors will be important to determine. Two other statin trials have also reported a slightly higher rate of diabetes with statin treatment compared with placebo (27, 28 ) .
Potential Implications of JUPITER on Current Practice Guidelines
There are several potential far-reaching implications of JUPITER for clinical practice and public health. First, the public health message is simple. Apparently, healthy men 50 years of age and older and women 60 years of age and older could undergo hsCRP testing combined with standard lipid measurement if there is uncertainty as to whether they qualify for lifelong statin therapy. In individuals with a family history of prema- ture coronary disease, it is reasonable to measure hsCRP along with lipids at an even earlier age. Individuals with increased hsCRP concentrations could then be offered statin therapy after a reasonable trial of lifestyle therapy, even if their LDL-C concentrations are not increased. Up to half of CVD events and one fifth of all-cause deaths may be prevented with appropriate statin therapy in these individuals, with a very low adverse-effect profile. Thus, targeting individuals who have high hsCRP concentrations despite typical or low LDL-C concentrations with statin therapy provides a direct approach for extending the benefit of prophylactic statins to asymptomatic populations with average lipid concentrations, populations that currently would not generally be considered eligible for statin therapy for primary prevention of CVD.
Second, the results of JUPITER should greatly simplify clinical practice for the primary prevention of CVD for a large proportion of individuals. Current North American and European prevention guidelines recommend the use of risk-prediction models, such as the ATP III (Framingham) risk equations and the European SCORE, which incorporate several traditional risk factors to estimate global CVD risk in asymptomatic individuals. The intensity of treatment of dyslipidemia and the use of other preventive therapies, such as aspirin, are then tailored to these risk categories, with low risk being generally defined as a 10-year absolute risk of a hard coronary event of Ͻ5% to 10% and high risk being defined as Ͼ20% (17 ) . One major limitation of these global risk scores is that they are not performed widely in clinical practice. In addition, only a small proportion of asymptomatic US adults (Ͻ1% of women and approximately 5% of men) are classified as "high risk" for CVD with such risk scores. Thus, there is an unfulfilled need for better and simpler risk assessment in asymptomatic individuals.
hsCRP testing along with lipid measurement in middle-aged individuals without known CVD readily identifies a relatively large group of individuals with hsCRP concentrations Ն2 mg/L who are at significantly higher risk compared with individuals with hsCRP concentrations Ͻ2 mg/L. This strategy is equally applicable to men and women and consolidates risk stratification in individuals with high hsCRP concentrations. In a multiethnic study of asymptomatic individuals, approximately 30% of participants (49% of women and 27% of men) with intermediate-risk In addition to statin therapy, individuals with increased hsCRP concentrations may also benefit from low-dose aspirin therapy. In asymptomatic men in the Physicians' Health Study, the magnitude of the benefit from aspirin use was positively related to the baseline hsCRP concentration (30 ) . Men with hsCRP concentrations Ն2 mg/L had an approximately 50% reduction in incident myocardial infarction with low-dose aspirin therapy, compared with smaller reductions in those with lower hsCRP concentrations. In contrast, there are no data to suggest that higher hsCRP concentrations modify the effect of low-dose aspirin therapy on incident CVD in asymptomatic women (Women's Health Study) (31 ) . In this study, women older than 65 years benefited from low-dose aspirin for CVD prevention. Interestingly, a recent report for the same cohort of women found that carriers of a variant in the gene encoding apolipoprotein A had higher lipoprotein(a) concentrations and a Ͼ50% reduction in incident CVD from low-dose aspirin, compared with noncarriers, who did not benefit from aspirin (32 ) . In the future, genotyping of CRP polymorphisms in individuals at risk for CVD may potentially identify those at highest risk for poor outcomes and in whom CRP-targeting therapy may be of most benefit.
For asymptomatic individuals with low concentrations of both LDL-C and hsCRP and optimal CVD risk factors, even a doubling or tripling of risk among these very low-risk individuals (e.g., from 1% to 3% over a 10-year period) would not change their risk category and should not greatly change physician or patient behavior because the absolute risk of CVD remains low.
Third, the number needed to treat to prevent a composite CVD event over a 5-year period in JUPITER is calculated at 25 individuals, which is relatively small and in the range deemed to be cost-effective (17 ) .
WOSCOPS (West of Scotland Coronary Prevention
Study) first demonstrated the benefit of statins for asymptomatic individuals with a high LDL-C concentration, whereas AFCAPS/TexCAPS extended the use of statins for asymptomatic individuals (predominantly men) with an average total-cholesterol concentration but a low HDL-C concentration. The number needed to treat in primary-prevention studies to prevent a major coronary event (often defined as coronary death or myocardial infarction) has been estimated at 60, whereas the number needed for secondary prevention is estimated at 33 (33 ) . JUPITER extends the use of statins to asymptomatic individuals with an average LDL-C concentration but a high hsCRP concentration (Table 3) .
Finally, the benefits of statins may extend beyond LDL-C lowering because of their effects on hsCRP lowering; however, because JUPITER tested an agent that reduces both LDL-C and hsCRP, the question remains as to whether lowering inflammation per se would lower CVD risk. LDL-C reductions of approximately 50% and hsCRP reductions of approximately 35% were observed in JUPITER in the intervention arm, compared with placebo, with about a 5% increase in HDL-C. In prior statin trials, the mean LDL-C concentration was reduced by 45 mg/dL (1.16 mmol/L), corresponding to a mean relative reduction in LDL-C concentration of 28%, and this reduction was associated with an approximately 20%-30% relative-risk reduction in hard coronary events (myocardial infarction and coronary death). The approximately 50 mg/dL (1.29 mmol/L) mean reduction in LDL-C concentration with statin therapy in JUPITER is similar to that found in prior statin trials on an absolute scale but is greater than prior trials on a percentage (or relative) basis. This finding is explained by the JUPITER patient population having lower baseline LDL-C concentrations compared with prior trials, such that an absolute reduction of 50 mg/dL (1.29 mmol/L) in JUPITER would translate into a greater percent LDL-C lowering compared with prior trials. More studies are needed to determine whether hsCRP reduction alone, independent of LDL-C reduction, produces a net clinical benefit.
LIFESTYLE AND BEHAVIORAL INTERVENTIONS
Weight reduction, smoking cessation, and exercise are recommended interventions for patients at risk for CVD or diabetes, and these interventions have been shown to lower hsCRP concentrations much more than their effects on LDL-C lowering. A recent study examined the extent to which risk factors may explain the cardioprotective benefit of physical activity (34 ) . The risk factors investigated in this study explained, in sum, approximately 60% of the activity-related reduction in CVD incidence. Inflammatory/hemostatic biomarkers (hsCRP, fibrinogen, and soluble intracellular adhesion molecule 1) provided the largest contribution to lowered risk (33%), followed by blood pressure (27%), lipids (19%), body mass index (10%), and glucose abnormalities (9%).
Lifestyle interventions should emphasize both increasing physical activity and dietary interventions aimed at obtaining and maintaining an ideal body weight. In a large study of asymptomatic adult women that compared physically active women of typical weight (energy expenditure, Ն1000 kcal/week; body mass index, 18.5-24.9 kg/m a Class I, conditions for which there is evidence and/or general agreement that a given procedure is useful and effective; class II, conditions for which there is conflicting evidence and/or divergence of opinion about the usefulness/efficacy of a procedure or treatment; class IIa, weight of evidence/opinion is in favor of usefulness/efficacy. b CHD, coronary heart disease.
concentrations of hsCRP may be important in the overall changes observed with intervention studies (36 ) .
Monitoring of hsCRP along with LDL-C in Statin
Therapy: A Potential Therapeutic Goal?
When high-risk patients with known CVD receive statin therapy, the best long-term clinical outcomes occur among those who achieve concentrations of LDL-C Ͻ70 mg/dL (Ͻ1.81 mmol/L) and hsCRP Ͻ2 mg/L. In the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22) and A-to-Z (Aggrastat-toZocor) trials, achievement of a low hsCRP concentration (Ͻ2 mg/L) and achievement of an LDL-C concentration Ͻ70 mg/dL (Ͻ1.81 mmol/L) produced similar rates of reduction of coronary events and improvement in survival, with better outcomes seen in individuals with both low LDL-C and low hsCRP values, compared with those with low LDL-C and high hsCRP concentrations (22, 37 ) .
Similar results have been observed in individuals with stable coronary disease, and those who achieve low hsCRP concentrations on statin therapy have reduced risk of stroke (38 ) and regression of atherosclerosis as assessed by intravascular ultrasonography (21 ) . These data, along with results from other clinical trials (22, 37 ) , suggest that achievement of a low hsCRP concentration after initiation of statin therapy may be as important a therapeutic goal as achieving a very low LDL-C concentration. Reason would suggest the usefulness of hsCRP measurement in secondary-prevention patients who have achieved LDL-C goals on low or moderate statin therapy, because the finding of a high hsCRP concentration may warrant further intensification of statin therapy, although this strategy remains to be formally validated in a prospective trial. We await further data from JUPITER regarding the combined use of achieved concentrations of hsCRP and LDL-C in asymptomatic patients on therapy.
Conclusions
The recently published results of the JUPITER trial join those of previous landmark statin trials and will likely lead to changes in current guideline recommendations regarding the use of hsCRP in clinical practice. Table 3 summarizes our proposed recommendations according to the level of supportive evidence. Because of its potential impact on public health, the JUPITER trial represents an extremely important step in understanding the links between inflammation, statin therapy, and the prevention of CVD, with the potential for substantially impacting our approach to cardiovascular prevention and treatment.
